In This Section

Research Funding Impact

Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.

Loading...
Leveraging TTFields for Residual Glioblastoma Disease

Leveraging TTFields for Residual Glioblastoma Disease

Sara G.M. Piccirillo, PhD, was inspired to study glioblastoma whilst an undergraduate student at the National Carlo Besta Neurological Institute in her hometown of Milan, Italy. Now an assistant professor at the University of New Mexico Health Sciences Center, Dr. Piccirillo, was awarded the AACR-Novocure Tumor Treating Fields (TTFields) Research Grant in 2021 to investigate the impact of TTFields on residual glioblastoma disease.

Dr. Chloe Steen: Dedicated to Dissecting Tumor Microenvironments

Dr. Chloe Steen: Dedicated to Dissecting Tumor Microenvironments

Led by a fascination with Lymphoma, Chloe Steen, PhD, has dedicated her research and career to developing and employing computational methods for dissecting the tumor microenvironment of lymphoma, and other types of cancer. Here, she shares how receiving 2019 AACR-AstraZeneca Lymphoma Research Fellowship represented a key stepping stone in her career.

Impacting Community through Community

Impacting Community through Community

A growing share of US adult smokers – Hispanic/Latino adults – have been found to be less likely to receive advice to quit and use proven cessation treatments than non-Hispanic white adults. 2021 AACR-Genentech Cancer Disparities Fellow Francisco Cartujano, MD, seeks to address tobacco-related disparities in Latinos by promoting smoking cessation and physical activity using a mobile intervention.

Targeting TNBC with an MDM2- PROTAC

Targeting TNBC with an MDM2- PROTAC

Triple negative breast cancer (TNBC) is an aggressive cancer with high rates of p53 inactivation and lower survival rates than other breast cancer types due to increased metastasis and relapse (1). Owing to the frequent inactivation of p53, compounds that inhibit p53 from binding to its negative regulator, MDM2, are ineffective in TNBC. In a recent study published in Cancer Discovery, Dr. Eischen and her colleagues used an MDM2-targeted PROteolysis TArgeting Chimera (PROTAC) to reveal the requirement for MDM2 in p53 inactivated TNBC and identify a new therapeutic target for the disease.